Spanish biochemist Mariano Barbacid has achieved what his research team describes as complete and lasting regression of pancreatic tumors in laboratory mouse models, using a combination of three drugs that caused cancer cells to self-destruct. The breakthrough, conducted at the National Centre for Oncological Research (CNIO), represents the first time researchers have achieved such comprehensive results against pancreatic cancer in experimental settings.

The treatment approach combines three medications that work together to trigger what researchers call programmed cell death in pancreatic cancer cells. According to research findings, the therapy demonstrated complete tumor elimination with low toxicity in the animal models tested. Pancreatic cancer remains one of the most lethal forms of cancer, with survival rates significantly lower than other major cancer types.

Funding Campaign for Human Trials

Barbacid has launched a public fundraising campaign seeking 3.5 million euros to advance the research toward human clinical trials. The scientist estimates that with adequate funding, the treatment could progress to human testing within two to three years. Hundreds of patients have reportedly attempted to contact the research center since the announcement, though the treatment remains in experimental stages and unavailable for human use.

The research has generated significant public attention, with thousands of people calling for Barbacid to receive the Nobel Prize in Medicine for his work in oncological research. His career spans decades of cancer research, and he is recognized as one of the most influential figures in global oncology studies. The current breakthrough builds on years of research into targeted cancer therapies and combination drug approaches.

Scientific Community Response

Some experts in the scientific community have raised questions about potential conflicts of interest surrounding the public fundraising campaign, noting the unusual nature of scientists directly soliciting public funds for research advancement. However, supporters argue that the urgency of pancreatic cancer treatment development justifies alternative funding approaches when traditional research funding may be insufficient or too slow.

The research team emphasizes that while the mouse model results are promising, significant additional testing and regulatory approval processes must be completed before any human applications can be considered. Clinical trials involving human patients require extensive safety testing and regulatory oversight that can take several years to complete, even with adequate funding in place.